Citation 105646

VAN ACKER,SABE: VAN DEN BERG,DJ: TROMP,MNJL: GRIFFIOEN,DH: VAN BENNEKOM,WP: VAN DER VIJGH,WJF: BAST,A:. (1996). STRUCTURAL ASPECTS OF ANTIOXIDANT ACTIVITY OF FLAVONOIDS.. 20(3)

Citation Details

Title	STRUCTURAL ASPECTS OF ANTIOXIDANT ACTIVITY OF FLAVONOIDS.
Authors	VAN ACKER,SABE: VAN DEN BERG,DJ: TROMP,MNJL: GRIFFIOEN,DH: VAN BENNEKOM,WP: VAN DER VIJGH,WJF: BAST,A:
Year	1996
Volume	20
Issue	3

Summary

Year: 1996

Journal: Unknown

Organisms and Their Experiments (1)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MYRICETIN	ACTIVE
2	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MYRICETIN	WEAK ACTIVITY
3	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	WEAK ACTIVITY
4	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	WEAK ACTIVITY
5	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	WEAK ACTIVITY
6	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FISETIN	ACTIVE
7	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FISETIN	WEAK ACTIVITY
8	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FISETIN	WEAK ACTIVITY
9	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	WEAK ACTIVITY
10	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	WEAK ACTIVITY
11	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	WEAK ACTIVITY
12	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	WEAK ACTIVITY
13	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	WEAK ACTIVITY
14	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	WEAK ACTIVITY
15	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALANGIN	WEAK ACTIVITY
16	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALANGIN	WEAK ACTIVITY
17	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALANGIN	WEAK ACTIVITY
18	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGENIN	ACTIVE
19	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGENIN	INACTIVE
20	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGENIN	INACTIVE
21	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGIN	INACTIVE
22	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGIN	INACTIVE
23	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	NARINGIN	INACTIVE
24	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERETIN	WEAK ACTIVITY
25	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERETIN	INACTIVE
26	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERETIN	INACTIVE
27	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERIDIN	WEAK ACTIVITY
28	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERIDIN	INACTIVE
29	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HESPERIDIN	INACTIVE
30	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	TAXIFOLIN	ACTIVE
31	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TAXIFOLIN	WEAK ACTIVITY
32	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TAXIFOLIN	WEAK ACTIVITY
33	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	ACTIVE
34	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	INACTIVE
35	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	INACTIVE
36	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DIOSMIN	ACTIVE
37	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIOSMIN	INACTIVE
38	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIOSMIN	INACTIVE
39	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	WEAK ACTIVITY
40	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	WEAK ACTIVITY
41	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	WEAK ACTIVITY
42	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	ACTIVE
43	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	WEAK ACTIVITY
44	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	ACTIVE
45	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORETIN	ACTIVE
46	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORETIN	WEAK ACTIVITY
47	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORETIN	WEAK ACTIVITY
48	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORIDZIN	INACTIVE
49	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORIDZIN	INACTIVE
50	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PHLORIDZIN	INACTIVE
51	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CYANIDIN	WEAK ACTIVITY
52	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CYANIDIN	WEAK ACTIVITY
53	ANTIOXIDANT ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PELARGONIDIN	INACTIVE
54	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PELARGONIDIN	WEAK ACTIVITY
55	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PELARGONIDIN	WEAK ACTIVITY

Citation 105646

Citation Details

Summary

Organisms and Their Experiments (1)

Unknown organism

Show SPARQL Queries (1)

Query 1